The CRISPR-Cas9 gene-editing technique - CML - Chronic Myeloid Leukemia
Scientists at the Salamanca Cancer Research Center (CIC) (Spain) have used the CRISPR-Cas9 gene-editing technique to eliminate the oncogene that produces chronic myeloid leukemia. In an article published by the Oncotarget magazine they show that in this way the tumor mouse cells revert to their normal state. If researchers can reproduce the results with patient cells, they would have an effective tool to treat the disease.
Extract of La edición de genes permite revertir células de leucemia mieloide crónica a su estado normal.
VIDEOS
What you need to know about CRISPR | Ellen Jorgensen
October 24, 2016, TED
What is CRISPR?
February 16 2016, Bozeman Science
How CRISPR lets us edit our DNA | Jennifer Doudna
November 12, 2015, TED
What you need to know about CRISPR | Ellen Jorgensen
October 24, 2016, TED
What is CRISPR?
February 16 2016, Bozeman Science
How CRISPR lets us edit our DNA | Jennifer Doudna
November 12, 2015, TED
ARTICLES
The Nobel Prize in Chemistry 2020 was awarded jointly to Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing."
October 7, 2020, Nobel Prize
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis
August 5, 2020, BioRxiv
Finding leukemia's weakness using genome-wide CRISPR technology
April 20, 2020, Medical Xpress
Scientists Bet for Genetic 'Edition' of Cancer
March 8, 2017, Prensa Latina
CRISPR-Cas9: from Genome Editing to Cancer Research
November 4, 2016, NCBI
ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts
November 26, 2015, NCBI
Genetic screens in human cells using the CRISPR/Cas9 system
December 12, 2013, NCBI
The Nobel Prize in Chemistry 2020 was awarded jointly to Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing."
October 7, 2020, Nobel Prize
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis
August 5, 2020, BioRxiv
Finding leukemia's weakness using genome-wide CRISPR technology
April 20, 2020, Medical Xpress
Scientists Bet for Genetic 'Edition' of Cancer
March 8, 2017, Prensa Latina
CRISPR-Cas9: from Genome Editing to Cancer Research
November 4, 2016, NCBI
ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts
November 26, 2015, NCBI
Genetic screens in human cells using the CRISPR/Cas9 system
December 12, 2013, NCBI